6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-19), Coherus BioSciences's 6-1 Month Momentum % is -38.33%.
The industry rank for Coherus BioSciences's 6-1 Month Momentum % or its related term are showing as below:
CHRS's 6-1 Month Momentum % is ranked worse than 83.34% of 1519
companies
in the Biotechnology industry
Industry Median: -1.21
vs CHRS: -38.33
Competitive Comparison
For the Biotechnology subindustry, Coherus BioSciences's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus BioSciences 6-1 Month Momentum % Distribution
For the Biotechnology industry and Healthcare sector, Coherus BioSciences's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Coherus BioSciences's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Coherus BioSciences 6-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Coherus BioSciences's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Coherus BioSciences (Coherus BioSciences) Business Description
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CHRS has been successfully added to your